Published March 1, 2022
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses galcanezumab (Emgality), 120 mg/mL solution for subcutaneous injection.
- Indication: For the prevention of migraine in adults who have at least 4 migraine days per month.